Compliance with Tamoxifen and Arimidex in the adjuvant treatment of women with breast cancer
2007; Georg Thieme Verlag; Volume: 4; Issue: 02 Linguagem: Inglês
10.1055/s-2007-983032
ISSN1611-647X
AutoresM. Ziller, W. Holzhauer, Volker Ziller, U Wagner, P. Hadji,
Tópico(s)Estrogen and related hormone effects
ResumoObjectives: The level of compliance for pharmacological therapies in chronic diseases varies, but is predominantly low. With Tamoxifen (TAM), 23% and 50% of non compliance after 1 and 4 years have been reported. No data on Anastrozol has yet been reported. The aim of this study was to evaluate the compliance rate in women with breast cancer on treatment with TAM or ANA.
Referência(s)